List of Agents Available Under CTEP Collaborative Agreements for Clinical and Non-clinical Studies

Clinical Use

The clinical research supply of the CTEP agents, below, is largely for the National Clinical Trials Network (NCTN) and the Experimental Therapeutics Clinical Trials Network (ETCTN), however investigators from certain NCI-designated Cancer Centers not affiliated with these networks may submit a LOI. If approved, investigators may receive full ETCTN support for the clinical trial.

NOTE: It is very important for anyone thinking of developing an LOI to first communicate with the appropriate drug monitor, as listed on the table, before initiating work on the LOI.

Non-Clinical Use

The CTEP agents, below, are available to all requestors after NCI receives the industry supplier’s approval for the proposed research. For requests other than agents from AstraZeneca, please use the Non-clinical Request Form found at: Non-clinical Request. For AstraZeneca agents please use the AZ Non-clinical Request Form. For any other questions, please email NCICTEPRequests@mail.nih.gov.

OTHER AGENTS: If the agent you are looking for is not on this list please also check the NCI Formulary.

NOTE: this list can be sorted by clicking on any of the header names. For an Excel Spreadsheet of these agents please click here.

CAUTION: The table is not a 'live' document. It is updated about 4 times per year, so should never be assumed to contain the most recent changes. Please feel free to contact the appropriate drug monitor, as listed on the table to confirm accuracy.

Agents Available Under CTEP Collaborative Agreements for Clinical and Non-clinical Studies as of 12/12/2024

Agent Name	Alternate Name	Pharmaceutical Collaborator	NSC Number	Drug Monitor	Mechanism of Action	Targets	Classes
Acalabrutinib		AstraZeneca	806311	Ivy	selectively inhibits Bruton’s tyrosine kinase (BTK) with minimal effects on TEC, EGFR, and ITK signaling.	Bruton’s tyrosine kinase (BTK)	Small Molecule
Actimab-A		Actinium Pharmaceuticals, Inc.	843488	Pelosof	Antibody Radioconjugate comprising the alpha-particle emitting radionuclide actinium-225 (Ac225) conjugated to lintuzumab, a humanized anti-CD33 monoclonal antibody	CD33+ myeloid-derived suppressor cells (MDSCs)	Antibody Radioconjugate
AMG510	Satorasib	Amgen	825510	Pelosof	Inhibits G12C-mutated KRAS	mutated KRAS protein	Small Molecule
Amivantamab	JNJ-61186372	Janssen Scientific Affairs, LLC	842127	Pickett	Inhibits EGFR and MET signaling	Extracellular domains of EGFR and MET	Bispecific Antibody
APG-1252	Pelcitoclax	Ascentage	831685	Gore	Inhibits B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma — extra-large (Bcl-xL)	anti-apoptotic Bcl-2 family proteins, including Bcl-2, Bcl-xL, Bcl-w, and Mcl-1	Small Molecule
ASTX660	Tolinapant	Taiho Oncology	842224	Gore	A dual antagonist of inhibitors of apoptosis proteins X-linked inhibitor of apoptosis protein (XIAP) and (cellular inhibitor of apoptosis proteins 1/2 (cIAP1/2)	Inhibitors of XIAP and cIAP1/2	Small Molecule
ASTX7272	Fixed-Dose Combination of cedazuridine and decitabine	Taiho Oncology	820631	Pelosof	DNA methyltransferase (DNMT) inhibitor	DNA methyltransferase	Small Molecule
Atezolizumab	MPDL3280A	Genentech	783608	Chen	Targets PD-L1 expressed on tumor and infiltrating immune cells, preventing binding to PD-1 and B7.1	programmed cell death ligand 1 (PD-L1)	Monoclonal Antibody
AZD5363	Capivasertib	AstraZeneca	782347	Said	Inhibits all AKT isoforms	AKT	Small Molecule
Balstilimab5	AGEN2034	Agenus	853950	Pickett	Binds PD-1 to prevent the interaction between the receptor and its ligands.	PD-1	Monoclonal Antibody
Belinostat	PXD 101	Acrotech Biopharma	726630	Pelosof	Histone deacetylase inhibition	Histone deacetylase	Hydroxamic acid
Bevacizumab	rhuMAb VEGF	Genentech	704865	Pickett	Binds VEGF to prevent its binding to VEGFR; angiogenesis inhibition	VEGF	Monoclonal Antibody (Humanized)
Blinatumomab	AMG-103, MT-103	Amgen	765986	Pickett	bispecific (BiTE specific) antibody targeting CD19	CD19	Monoclonal Antibody
Botensilimab	AGEN1181	Agenus	853990	Pickett	Binds to CTLA-4 to inhibits the CTLA-4-mediated downregulation of T-cell activation.	CTLA-4	Monoclonal Antibody
Brentuximab vedotin	SGN-35	Seattle Genetics	749710	Pickett	An antibody drug conjugate targeting CD30 and using an MMAE payload	CD30	Antibody-Drug Conjugate
CA-4948	Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4) Inhibitor	Curis, Inc.	824184	Pickett	Inhibits TLR and IL-1R signaling; Inhibits myddosome signaling; inhibits NFkB activity	IRAK4 and IRAK4-L	Small Molecule
Cabozantinib	XL-184	Exelixis	761968	Said	c-Met; VEGFR2 inhibition	c-Met; VEGFR2	Small Molecule
Camonsertib	RP-3500	Repare Therapeutics	851929	Gore	Selective ATR Kinase Inhibitor (ATRi)	Ataxia telangiectasia and Rad3-related (ATR) kinase	Small Molecule
CBX-12	Alphalex-exatecan	Cybrexa 2, Inc	828474	Said	Alphalex conjugate that contains a topoisomerase I inhibitor exatecan	Topoisomerases I	Peptide Drug Conjugate
CDX-1140		Celldex	841752	Pickett	Agonist anti-CD40 monoclonal antibody that inhibits cancer cell proliferation or triggers apoptotic cell death	Human CD40	Monoclonal antibody (mAb)
Cediranib1	AZD2171	AstraZeneca	732208	Ivy	Angiogenesis inhibitor, VEGFR1, VEGFR2, VEGFR3, PDGFR alpha and beta, FGFR1	VEGFRs, PDGFRs, FGFR1	Small Molecule
Cemiplimab	REGN2810	Regeneron	788843	Pickett	Inhibits programmed death receptor-1	Programmed cell death 1 (PD-1) on the surface of immune cells	Monoclonal Antibody
Cirtuvivint		Biosplice Therapeutics, Inc	835563	Gore	Inhibits CDC-Like Kinases (CLK) and Dual-Specificity Tyrosine-Regulated Kinases (DYRK)	CLK/DYRK kinase	Small Molecule
Dabrafenib mesylate1	GSK2118436B	Novartis	763760	Chen	BRAF inhibition of BRAFV600 mutations	BRAF	Small Molecule
Darolutamide	BAY-1841788	Bayer	815949	Pelosof	A novel nonsteroidal androgen receptor (AR) antagonist	androgen receptor (AR)	Small Molecule
DAY101	Tovorafenib	Day One Biopharmaceuticals, Inc.	800798	Said	A selective Type II pan-RAF kinase inhibitor	pan-RAF kinase	Small Molecule
Dinutuximab	Ch14.18	United Therapeutics	764038	Chen	Antibody against GD2	GD2	Monoclonal Antibody (chimeric)
Durvalumab	MEDI4736	AstraZeneca/Medimune	778709	Chen	Check point inhibitor. Antibody against programmed cell death ligand 1 (PD-L1)	PD-L1	Monoclonal Antibody
Fianlimab		Regeneron	847987	Pickett	Inhibits immune checkpoint receptor LAG-3	LAG-3 on T cells	Monoclonal Antibody
Giredestrant	GDC-9545	Genentech	840836	Pickett	Selective estrogen receptor degrader (SERD)	Competitively binds to the ligand binding-domain (LBD) of both wild-type and mutant estrogen receptor (ER)	Small Molecule
Glofitamab	RO7082859	Genetech	845088	Ko	promotes T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells	bivalency for CD20 on B cells and monovalency for CD3 on T cells.	Bispecific antibody
Iberdomide		Bristol Myers Squibb	833899	Said	Immunomodulatory therapeutic	Induces degradation of transcription factors Aiolos and Ikaros	Small Molecule
idUrd Prodrug	IPdR	NCI	726188	Pelosof	Prodrug of iododeoxyuridine	DNA polymerase	Small Molecule
IMC-F106C		Immunocore	853198	Ko	An immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC) for the treatment of cancers positive for the tumor-associated antigen PRAME.	TCR bispecific protein targeting CD3 and PRAME	Monoclonal Antibody
Inavolisib	GDC-0077	Genentech	843575	Said	Selectively inhibits the Class I PI3Kα isoform (p110α), with minimal inhibition of the Class I PI3K β, γ, and δ isoforms	Class I PI3Kα isoform (p110α)	Small Molecule
Interleukin-12	IL-12	NCI	672423	Streicher	Made mainly by dendritic cells and macrophages. Causes other immune cells to make cytokines and increases the growth of T lymphocytes. It may also block the growth of new blood vessels.	Binds to the IL-12 receptor found on activated T cells Upon binding, IL-12R-β2 provides binding sites for Tyk2 and Jak2, activating STAT4	Pleiotropic Cytokine
Interleukin-15	IL-15	NCI	745101	Streicher	Cytokine that regulates T and natural killer cell activation and proliferation. Shares many biological activities with interleukin 2	Activates JAK kinases, and phosphorylation/activation of transcription activators STAT3, STAT5 and STAT6.	Cytokine
Ipatasertib1	GDC-0068	Genentech	781451	Said	an ATP-competitive AKT inhibitor, blocks the phosphoinositide 3-kinase (PI3K)/AKT pathway	all three isoforms of AKT	small molecule
Larotrectinib		Bayer	788607	Pelosof	Highly-selective, tropomyosin receptor kinase (TRK) inhibitor	NTRK-1, NTRK-2, NTRK-3 gene fusions; TrkA/B/C fusion proteins	Small Molecule
Lutetium	Lu177 Dotatate	Novartis	815530	Pelosof	Radiopharmaceutical that binds to somatostatin receptor, is internalized and accumulates in lysosomes.	Somatostatin receptor	Radiopharmaceutical
M17743	VXc 400 or VRT 1363004	EMD Serono (Merck KGaA)	831851	Gore	Selectively inhibits ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase	ATR	Small Molecule
M3814	MSC2490484A	EMD Serono (Merck KGaA)	802447	Gore	DNA-PK inhibition, delays DNA repair of the DSB pathway in solid tumors and hematologic malignancies	DNA-dependent protein kinase (DNA-PK)	Small Molecule
METxMET	REGN5093	Regeneron	849708	Pickett	Binds to two distinct epitopes of MET, thus blocking HGF binding and induces internalization and degradation of MET	MET (receptor tyrosine kinase)	Bispecific Antibody
Mezigdomide		Bristol Myers Squibb Company		Said	Cereblon E3 ligase modulator (CELMoD), IKAROS family zinc finger 1 and 3 inhibitor, protein degrader	cereblon (CRBN)-E3 ligase, IKAROS family zinc finger 1&3	Small Molecule
Mirdametinib		SpringWorks Therapeutics, Inc.	755770	Said	Inhibits MAPK signaling pathway	MEK1 and MEK2	Small Molecule
Mosunetuzumab		Genentech	833090	Ko	Simultaneously targets CD20 on B-cells and CD3 on T-cells by redirecting endogenous T-cells to engage and eliminate tumor-specific CD20-expressing B-cells.	CD20 on B-cells and CD3 on T-cells	Full length IgG1 antibody
Nemvaleukin Alfa		Alkermes, Inc.	836408	Streicher	Binds to the IL-2R complex to preferentially activate memory cytotoxic	IL-2R complex	Engineered IL-2 variant
Osimertinib	AZD9291	AstraZeneca	781254	Said	3rd generation epidermal growth factor receptor mutation (mEGFR) inhibitor	mEGFR and the dominant acquired T790M resistance mutation	Small Molecule
Pembrolizumab	MK-3475	Merck	776864	Ko	Humanized IgG4 mAb against programmed death 1 receptor (PD-1)	PD-1	Antibody
Pidnarulex	CX-5461	Senhwa Biosciences, Inc.	845292	Gore	G-Quadruplex-stabilizer (Quinolone Derivative)	it causes replication fork stalling and promotes DNA damage resulting in cell death homologous recombination deficiency (HRD) tumors.	Small Molecule
Radium223	Radium223	Bayer	793433	Pelosof	alpha particle-emitting radionuclides		Radiopharmaceutical
Relatlimab4	BMS-986016	Bristol-Myers Squibb	783201	Streicher	inhibitor of the LAG-3 checkpoint receptor	LAG-3	Monoclonal Antibody
Sacituzumab Govitecan	IMMU-132; TRODELVY®	Gilead Sciences, Inc	820016	Pelosof	Trop-2 receptor targeted antibody-drug conjugate - inhibits topoisomerase I which leads to DNA damage leads to apoptosis of the target cells	Trop-2 receptor	Monoclonal Antibody
Sapanisertib	FTH-003	Faeth therapeutics, Inc.	768435	Said	Inhibits Rapamycin complex1/2 (TORC1/TORC2) kinase	TORC1/TORC2	Small Molecule
Savolitinib	AZD6094	AstraZeneca	785348	Pelosof	specific, small molecule inhibitor of the MET receptor kinase	cMet	Small Molecule
Selumetinib1	AZD6244	AstraZeneca	748727	Pelosof	MAPK/ERK Kinase (MEK) inhibition	MEK enzyme	Small Molecule
Talazoparib	BMN 673 (MDV 38000)	Pfizer	771561	Ivy	Polyadenosine 5’diphosphoribose[poly (ADP ribose)] Polymerase (PARP) inhibitor, PARylation inhibitor and PARP trapper, Class II, strong trapper. Binding prevents PARP-mediated DNA repair of single strand DNA breaks via base-excision repair	PARP 1 and 2 inhibitor	Small Molecule
Tazemetostat		Epizyme/Ipsen	791066	Pelosof	Inhibits Enhancer of zeste homolog 2 (EZH2)	EZH2	Small Molecule
Teclistamab		Janssen Research and Development, LLC	840815	Ko	Bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and BCMA expressed on the surface of malignant multiple myeloma B lineage cells and leads to cell death of the BCMA+ cells	BCMA+ malignant B cells	Bispecific antibody
Tin-117m-DTPA		Serene		Pelosof	Radiopharmaceutical that selectively accumulates in bone metastases		Radiopharmaceutical
Trametinib1	GSK112021	Novartis	763093	Chen	Potent and highly selective inhibitor of MEK1/2 activation and kinase activity	MEK enzyme	Small Molecule
Trastuzumab deruxtecan	DS-8201a	Daiichi Sankyo	807708	Pickett	HER2-targeted antibody-drug conjugate - inhibits topoisomerase I which leads to apoptosis of the target cells	Human Epidermal Growth Factor Receptor 2 (HER2)	Monoclonal Antibody-drug conjugate
Triapine		Nanopharmaceutics, Inc.	663249	Ivy	Ribonucleotide reductase (RR) inhibitor inhibits the metal binding subunit (M2) of RR, which is essential for DNA synthesis and repair.	DNA Synthesis(RR M2 subunit — Enzyme)	Small Molecule
Venetoclax	ABT-199	Abbvie/Genentech	766270	Gore	Bcl-2-selective inhibitor that disrupts Bcl-2 signaling in cells and rapidly induces multiple hallmarks of apoptotic cell death in Bcl-2-dependent tumor cells	Bcl-2 and with lower affinity to Bcl-XL and Bcl-w	Small Molecule
ZEN-3694	ZEN003694	Zenith Epigenetics Ltd.	824453	Pelosof	epigenetically regulates gene expression through BET inhibition, targeting BET proteins leads to inhibition of tumor growth in multiple cancer types, through cell cycle arrest and induction of senescence and apoptosis.	Bromodomain and Extra-Terminal motif (BET) inhibitor	Small Molecule
Z-endoxifen HCI		NCI	750393	Streicher	Endoxifen, a cytochrome P450 mediated tamoxifen metabolite, is an anti-estrogen	Targets estrogen receptor-alpha	Small Molecule

1 - Non-clinical requests only
2 - Only available for clinical studies
3 - Discuss with Dr. Gore before preparing/submitting an LOI
4 - Nivolumab and Ipilimumab are only available for use in combination with relatlimab. Discussion with the drug monitor prior to submitting an LOI is recommended.
5 - In Combination with botensilimab only